<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        8-5381-22
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1998
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DOBUTAMINE HCL 250MG-20ML VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DOBUTAMINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        31.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HOSPIRA AUSTRALIA " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HOSPIRA AUSTRALIA 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Australia Pty LTD
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C01CA07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dobutamine Concentrate belongs to a group of medicines known as inotropes, which make your heart beat more strongly.</p><p>In adults it is used:</p><p>&bull;&nbsp; in open heart surgery</p><p>&bull;&nbsp; to treat heart disease</p><p>&bull;&nbsp; to treat heart failure</p><p>&bull;&nbsp; in shock</p><p>&bull;&nbsp; as an alternative to exercise for stress testing the heart.</p><p>&nbsp;</p><p>Paediatric population</p><p>Dobutamine is indicated in all paediatric age groups (from neonates to 18 years of age) as inotropic support in low cardiac output hypoperfusion states resulting from decompensated heart failure, following cardiac surgery, cardiomyopathies and in cardiogenic or septic shock.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You</strong><strong> should not </strong><strong>&nbsp;</strong><strong>be given Dobutamine Concentrate if you:</strong></p><p>&bull;&nbsp; Are allergic to Dobutamine, sodium metabisulfite or any of the other ingredients in this injection.</p><p>&bull;&nbsp; suffer from high blood pressure due to a tumour near the kidney (Phaeocromocytoma).</p><p>&bull;&nbsp; have certain heart or blood vessel disorders. Dobutamine should not be used to detect poor blood supply to your heart (a cardiac stress test known as Dobutamine Stress Echocardiography)</p><p>Warnings and precautions:</p><p>Talk to your doctor or nurse if you have any of the following conditions:</p><p>&bull;&nbsp; have recently had a heart attack</p><p>&bull;&nbsp; have had a heart transplant</p><p>&bull;&nbsp; are asthmatic</p><p>&bull;&nbsp; have unstable angina</p><p>&bull;&nbsp; have heart disease</p><p>&bull;&nbsp; have high blood pressure</p><p>&bull;&nbsp; have any condition that would make exercise dangerous for you.</p><p>&nbsp;</p><p><strong><u>Children</u></strong></p><p>Increments in heart rate and blood pressure appear to be more frequent and intense in children than in adults. The new-born baby cardiovascular system has been reported to be less sensitive to dobutamine and hypotensive effect (low blood pressure) seems to be more often observed in adult patients than in small children. Accordingly, the use of dobutamine in children should be monitored closely.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p><strong>Other medicines and Dobutamine</strong>:</p><p><strong>Concentrate:</strong></p><p>Tell your doctor or nurse if you are &nbsp;taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. This is especially important with the following medicines as they may interact with your Dobutamine Concentrate:</p><p>&bull;&nbsp; beta blockers (medicines used to relieve certain heart conditions, anxiety and migraine).</p><p>&bull;&nbsp; anaesthetics.</p><p>&bull;&nbsp; entacapone a &nbsp;medicine &nbsp;to &nbsp;treat&nbsp; Parkinson&rsquo;s Disease).</p><p>&nbsp;</p><p>Pregnancy and breast feeding:</p><p>&nbsp;</p><p><strong>Tell your doctor or pharmacist if you are pregnant or intend to become pregnant.</strong></p><p>Dobutamine Hydrochloride Injection is not recommended for use during pregnancy. If there is a need to consider dobutamine during pregnancy, your doctor will discuss with you the benefits and risks of being given it.</p><p>&nbsp;</p><p><strong>Tell your doctor or pharmacist if you are breast-feeding or plan to breast-feed.</strong></p><p>It is not known whether Dobutamine Hydrochloride Injection passes into breast milk. Your doctor or pharmacist will discuss the possible risks and benefits of being given dobutamine while you are breast-feeding.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>&nbsp;</strong></p><p><strong>Tell your doctor or pharmacist if you have or have had any medical conditions, especially the following:</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast or irregular heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other heart problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low potassium levels (hypokalaemia)</p><p>&nbsp;</p><p><strong>If you have not told your doctor or pharmacist about any of the above, tell them before you start being given Dobutamine Hydrochloride Injection.</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>Driving and using machines:</p><p>You should not drive or use machinery if you are affected by the administration of Dobutamine Concentrate.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your nurse or doctor will give you the injection. Your doctor will decide the correct dosage for you and how and when the injection will be given.</p><p>Since the injection will be given to you by a doctor or nurse, it is unlikely that you will be given too much. If you think you have been given too much,</p><p>feel sick, are sick, feel anxious, feel palpitations, have a headache, feel short of breath or have chest pain you must tell the person giving you the injection.</p><p>&nbsp;</p><p><strong>Use in children</strong></p><p>Your child will be given the injection by a nurse or doctor who will decide the correct dosage for your child and how and when the injection will be given.</p><p>If you have any further questions or concerns on the use of this medicine for your child ask the doctor or nurse giving the injection.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Dobutamine Concentrate can cause side effects, although not everybody gets them.</p><p>Your doctor will examine your heart before giving you Dobutamine Concentrate to decide if you are suitable to receive the drug.</p><p>&nbsp;</p><p>&nbsp;</p><p>The following side-effects have been reported:</p><p>&nbsp;&nbsp;</p><p><u>Very</u><u> </u><u>common (more than 1 in 10 patients)</u></p><p>-&nbsp; increased heart rate</p><p>-&nbsp; chest pain</p><p>-&nbsp; heartbeat disturbances</p><p><u>Common</u><u> </u><u>(in less than 1 in 10, but more than 1 in</u> <u>100 patients)</u></p><p>-&nbsp; blood pressure increase or decrease</p><p>-&nbsp; narrowing of the blood vessels (vasoconstriction)</p><p>-&nbsp; irregular heartbeat (palpitations)</p><p>-&nbsp; asthma-like symptoms (bronchospasm)</p><p>-&nbsp; shortness of breath</p><p>-&nbsp; increase in white blood cells (eosinophilia)</p><p>-&nbsp; inhibition of blood clot formation</p><p>-&nbsp; rash (exanthema)</p><p>-&nbsp; fever</p><p>- inflammation of&nbsp; the &nbsp;vein&nbsp; at&nbsp; the&nbsp; injection &nbsp;site</p><p>(phlebitis)</p><p><u>Uncommon</u><u> </u><u>(in less than 1 in 100, but more than 1 in 1000 patients)</u></p><p>-&nbsp; fast contractions of the ventricles of the heart</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (ventricular tachycardia)</p><p>-&nbsp; uncontrolled contractions of the ventricles of the heart</p><p><strong>&nbsp;&nbsp; </strong>&nbsp;(ventricular fibrillation)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>heart</strong><strong> </strong><strong>attack </strong><strong>(myocardial infarction)</strong></p><p><u>Very</u><u> </u><u>rare (in less than 1 in 10 000, including</u> <u>isolated </u><u>cases)</u></p><p>-&nbsp; slow heartbeat (bradycardia)</p><p>-&nbsp; not&nbsp; &nbsp;enough&nbsp; &nbsp;blood&nbsp; &nbsp;supplied&nbsp; &nbsp;to&nbsp; &nbsp;the&nbsp; &nbsp;heart (myocardial ischaemia)</p><p>-&nbsp; low potassium (hypokalaemia)</p><p>-&nbsp; spots on the skin (petechial bleeding)</p><p>-&nbsp; heart block</p><p>-&nbsp; narrowing of the blood vessels supplying the heart (coronary vasospasm)</p><p><u>Not</u><u> known&nbsp; (cannot&nbsp; &nbsp;be&nbsp; &nbsp;estimated&nbsp; &nbsp;from&nbsp; &nbsp;the</u> <u>available data)</u></p><p>-&nbsp; chest&nbsp; pain&nbsp; caused&nbsp; by&nbsp;&nbsp; stress&nbsp;&nbsp;&nbsp; (stress cardiomyopathy)</p><p>-&nbsp; <!--[if gte vml 1]><v:group
 id="_x0020_109" o:spid="_x0000_s1026" style='position:absolute;left:0;
 text-align:left;margin-left:1.35pt;margin-top:3.8pt;width:12.25pt;height:12.25pt;
 z-index:-251659264;mso-position-horizontal-relative:page' coordorigin="27,76"
 coordsize="245,245" o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" o:allowincell="f">
 <v:shape id="_x0020_110" o:spid="_x0000_s1027" style='position:absolute;
  left:50;top:99;width:200;height:200;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="200,200" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m199,99r-2,23l189,143r-11,18l163,177r-19,12l124,196r-23,3l78,197,57,190,38,178,23,163,11,145,3,125,,102,2,79,9,58,20,39,35,23,53,11,73,3,95,r24,2l141,9r19,11l175,35r13,17l196,72r3,22l199,99xe"
  filled="f" strokeweight=".25pt">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="199,99;197,122;189,143;178,161;163,177;144,189;124,196;101,199;78,197;57,190;38,178;23,163;11,145;3,125;0,102;2,79;9,58;20,39;35,23;53,11;73,3;95,0;119,2;141,9;160,20;175,35;188,52;196,72;199,94;199,99"
   o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
 </v:shape><v:shape id="_x0020_111" o:spid="_x0000_s1028" style='position:absolute;
  left:30;top:199;width:240;height:20;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="240,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l240,e" filled="f" strokeweight=".25pt">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;240,0"
   o:connectangles="0,0"/>
 </v:shape><v:shape id="_x0020_112" o:spid="_x0000_s1029" style='position:absolute;
  left:150;top:79;width:20;height:240;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="20,240" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l,240e" filled="f" strokeweight=".25pt">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;0,240"
   o:connectangles="0,0"/>
 </v:shape><v:shape id="_x0020_113" o:spid="_x0000_s1030" style='position:absolute;
  left:90;top:140;width:120;height:119;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="120,119" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m45,l27,8,12,22,3,42,,68,7,88r14,16l40,114r24,4l86,112,103,99,114,80r5,-22l117,42,108,25,93,11,72,2,45,xe"
  fillcolor="black" stroked="f">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="45,0;27,8;12,22;3,42;0,68;7,88;21,104;40,114;64,118;86,112;103,99;114,80;119,58;117,42;108,25;93,11;72,2;45,0"
   o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
 </v:shape><v:shape id="_x0020_114" o:spid="_x0000_s1031" style='position:absolute;
  left:90;top:199;width:120;height:20;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="120,20" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l120,e" filled="f" strokecolor="white" strokeweight=".25pt">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;120,0"
   o:connectangles="0,0"/>
 </v:shape><v:shape id="_x0020_115" o:spid="_x0000_s1032" style='position:absolute;
  left:150;top:139;width:20;height:120;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="20,120" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBn58ERwQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/fa8Iw
EH4f+D+EE/Y2U4cW7YxFhsJehkwFX2/NrSlrLjWJtfvvl8HAt/v4ft6qHGwrevKhcaxgOslAEFdO
N1wrOB13TwsQISJrbB2Tgh8KUK5HDysstLvxB/WHWIsUwqFABSbGrpAyVIYshonriBP35bzFmKCv
pfZ4S+G2lc9ZlkuLDacGgx29Gqq+D1erwLZDV1/w7Leb+Xy/Xyzx8z3PlXocD5sXEJGGeBf/u990
mj+Dv1/SAXL9CwAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAAAAAA
AAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAAAA
AAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAGfnwRHBAAAA2wAAAA8AAAAA
AAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD1AgAAAAA=
" path="m,l,120e" filled="f" strokecolor="white" strokeweight=".25pt">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;0,120"
   o:connectangles="0,0"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="18" height="18" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png" />allergic reactions (hypersensitivity reactions) including symptoms of rash, fever, increase in white blood cells (eosinophilia) and asthma-like symptoms (bronchospasm)</p><p>-&nbsp; severe allergic reactions (anaphylactic reactions) and severe life-threatening asthmatic episodes possibly due to sensitivity to sodium metabisulfite (see Section 2)</p><p>-&nbsp; muscle cramp (myoclonus) in patients with severe renal failure receiving dobutamine</p><p>-&nbsp; abnormal heart function test (electrocardiogram ST segment elevation)</p><p>-&nbsp; inflammation&nbsp; &nbsp;of&nbsp; &nbsp;heart&nbsp; &nbsp;muscle (eosinophilic myocarditis) in heart transplant patients</p><p>-&nbsp; heart&nbsp; &nbsp;block (left&nbsp; &nbsp;ventricular&nbsp; &nbsp;outflow&nbsp; &nbsp;tract obstruction)</p><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>-&nbsp; fatal heart rupture</p><p>-&nbsp; restlessness</p><p>-&nbsp; feeling sick (nausea)</p><p>-&nbsp; headache</p><p>-&nbsp; pins and needles (paraesthesia)</p><p>-&nbsp; tremor</p><p>-&nbsp; increased desire to urinate (at high doses)</p><p>-&nbsp; feelings of heat and anxiety</p></td></tr></tbody></table><p>-&nbsp; muscle cramp (myoclonic spasm)</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or, pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&nbsp;</p><p>To reports any side effect(s):</p><p><strong>Saudi Arabia: </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):</p><ul><li>Fax: +966-11-205-7662</li><li>Call NPC at +966-11-2038222, Ext 2317-2356-2340</li><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Other GCC States:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Please contact the relevant competent authority</p><p><strong><em>&nbsp;</em></strong></p></td></tr></tbody></table><p><strong><em>&nbsp;</em></strong></p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor &nbsp;and pharmacist are responsible for the correct storage, use and disposal of this medicine</p><p>&nbsp;</p><p>&bull;&nbsp; store below 25C.</p><p>&bull;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&bull;&nbsp; Do not use this medicine after the expiry date which is stated on the carton/label. The expiry date refers to the last day of the month.</p><p>&bull;&nbsp; Do not use this medicine if you notice the solution is not clear and free of particles or if the container is damaged.</p><p>&bull;&nbsp; Your pharmacist will dispose of any medicine that remains unused.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>hydrochloride. Each 1 ml contains dobutamine hydrochloride equivalent to 12.5 mg dobutamine in a sterile solution for injection.</p><p>The other ingredients are sodium metabisulfite and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Dobutamine Concentrate is supplied in 20 ml clear glass vial, in cartons containing one vial. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder:</strong></p><p><strong>&nbsp;</strong>Pfizer&nbsp;Australia Pty Ltd, Australia</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Hospira Australia Pty Ltd, Australia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                August 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تنتمي ركازة دوبوتامين إلى مجموعة من الأدوية تعرف باسم المؤثرات في التقلص العضلي التي تجعل قلبك ينبض بشكل أقوى.</p><p dir="RTL">مع البالغين يستخدم:</p><p dir="RTL">&middot;&nbsp;&nbsp; في جراحة القلب المفتوح</p><p dir="RTL">&middot;&nbsp;&nbsp; لعلاج مرض القلب</p><p dir="RTL">&middot;&nbsp;&nbsp; لعلاج فشل القلب</p><p dir="RTL">&middot;&nbsp;&nbsp; في الصدمة</p><p dir="RTL">&middot;&nbsp;&nbsp; كبديل للتمارين في اختبار الجهد القلبي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">فئة الأطفال</p><p dir="RTL">يوصف دوبوتامين للأطفال في جميع المجموعات العمرية (بدءًا من حديثي الولادة حتى سن 18 عامًا) كداعم مؤثر في التقلص العضلي في حالات نقص التروية المرتبطة بانخفاض النتاج القلبي الذي يرجع إلى فشل القلب اللا معاوض، وبعد جراحة القلب، وفي حالات اعتلال عضلة القلب، والصدمة قلبية المنشأ أو الصدمة الإنتانية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">أ&zwnj;-&nbsp;&nbsp; <strong>موانع استعمال ركازة دوبوتامين: </strong></p><p dir="RTL"><strong>ينبغي عدم إعطائك ركازة دوبوتامين</strong> <strong>إذا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من حساسية تجاه دوبوتامين، أو ميتابيسلفيت الصوديوم، أو تجاه أي من المكونات الأخرى في هذه الحقن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من ضغط الدم المرتفع نتيجة لوجود ورم بالقرب من الكلية (ورم القواتم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من بعض الاضطرابات القلبية أو اضطرابات الأوعية الدموية. ينبغي عدم استخدام دوبوتامين للكشف عن ضعف إمداد الدم إلى قلبك (اختبار الجهد القلبي معروف باسم تخطيط صدى القلب بالمجهود باستخدام دوبوتامين)</p><p dir="RTL">ب&zwnj;-&nbsp;&nbsp;&nbsp; <strong>&nbsp;الاحتياطات عند استعمال دوبوتامين:</strong></p><p dir="RTL">تحدث إلى طبيبك أو الممرضة إذا كنت مصابًا بأي من الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت مؤخرًا بنوبة قلبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد قمت بعملية زراعة للقلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الربو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ذبحة صدرية غير مستقرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض بالقلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ضغط الدم المرتفع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي حالة قد تجعل التمارين تشكل خطرًا عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال </strong></p><p dir="RTL">تظهر الزيادات في معدل نبضات القلب وضغط الدم بصورة أكثر تكرارًا وقوة في الأطفال مقارنة بالبالغين. تم الإبلاغ عن أن الجهاز القلبي الوعائي في الأطفال حديثي الولادة أقل حساسية تجاه الدوبوتامين وأن التأثير الخافض لضغط الدم (ضغط الدم المنخفض) يبدو أكثر ملاحظة في المرضى البالغين مقارنة بالأطفال الصغار. وبالتالي، تنبغي مراقبة استخدام الدوبوتامين مع الأطفال عن كثب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج- التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">الركازة:</p><p dir="RTL">أخبر طبيبك أو<strong> </strong>الممرضة<strong> </strong>إذا كنت تتناول أو تستخدم أو قد تناولت مؤخرًا أو قد تتناول أي أدوية أخرى، بما في ذلك الأدوية التي يمكن الحصول عليها بدون وصفة طبية. هذا مهم بشكل خاص مع الأدوية التالية لأنها قد تتفاعل مع ركازة دوبوتامين التي تستخدمها:</p><p dir="RTL">&nbsp;حاصرات بيتا (أدوية تستخدم للتخفيف من شدة بعض الحالات القلبية والقلق والصداع النصفي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية التخدير</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنتاكابون (دواء لعلاج مرض باركنسون).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تتأثر هذه الأدوية بحقن هيدروكلوريد دوبوتامين أو قد تؤثر على مدى كفاءة عمل حقن هيدروكلوريد دوبوتامين.&nbsp; قد تحتاج إلى كميات مختلفة من دوائك، أو قد تحتاج إلى تناول أو استخدام أدوية مختلفة.&nbsp; سيقوم طبيبك أو الصيدلي بنصحك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يكون لدى طبيبك والصيدلي المزيد من المعلومات حول الأدوية التي ينبغي توخي الحذر عند استخدامها أو تجنب استخدامها أثناء إعطائك حقن هيدروكلوريد دوبوتامين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبري طبيبكِ أو الصيدلي إذا كنتِ حاملًا أو تنوين الحمل.</strong></p><p dir="RTL">لا يوصى باستخدام حقن هيدروكلوريد دوبوتامين أثناء الحمل. إذا كانت هناك حاجة للنظر في استخدام دوبوتامين أثناء الحمل، فسوف يناقش طبيبك معك الفوائد والمخاطر المترتبة على إعطائه لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبري طبيبكِ أو الصيدلي إذا كنتِ ترضعين رضاعة طبيعية أو تخططين للقيام بالرضاعة الطبيعية.</strong></p><p dir="RTL">ليس معروفًا ما إذا كانت حقن هيدروكلوريد دوبوتامين تمر إلى لبن الثدي أم لا. سيناقش طبيبكِ أو الصيدلي الفوائد والمخاطر المحتملة لإعطائكِ دوبوتامين أثناء قيامكِ بالرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي إذا كنت تعاني أو سبق لك أن عانيت من أي حالات طبية، خاصة التالي ذكرها:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط الدم المرتفع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة أو عدم انتظام ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات أخرى في القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات البوتاسيوم (نقص بوتاسيوم الدم)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا لم تكن قد أخبرت طبيبك أو الصيدلي بأي من الأمور المذكورة أعلاه، فأخبره قبل البدء في إعطائك حقن هيدروكلوريد دوبوتامين.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير دوبوتامين على القيادة واستخدام الآلات:</strong></p><p dir="RTL">ينبغي لك عدم القيادة أو استخدام الآلات إذا كنت تتأثر باستخدام ركازة دوبوتامين.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيقوم طبيبك أو الممرضة بإعطائك الحقن. سيقرر طبيبك الجرعة الصحيحة بالنسبة لك وكيف ومتى سيتم إعطاؤها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;الجرعة الزائدة من دوبوتامين</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">نظرًا لأن الحقن سيتم إعطاؤها لك من قبل طبيب أو ممرضة، فمن المستبعد أن تتلقى جرعة أكبر من اللازم. إذا كنت تعتقد أنه تم إعطاؤك جرعة أكبر من اللازم، أو كنت تشعر بالرغبة في التقيؤ، أو كنت تتقيأ، أو كنت تشعر بالقلق، أو كنت تشعر بخفقان، أو كنت تعاني من صداع، أو كنت تشعر بضيق في التنفس، أو كنت تعاني من ألم في الصدر، يجب عليك إخبار الشخص الذي يعطيك الحقنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتضمن أعراض الجرعة المفرطة من دوبوتامين الآثار الجانبية المذكورة أدناه بقسم &quot;الآثار الجانبية المحتملة&quot;، ولكنها عادة ما تكون ذات طبيعة أكثر شدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الاستخدام مع الأطفال</p><p dir="RTL">سيتم إعطاء طفلك الحقنة من قبل ممرضة أو طبيب وهو سيقرر الجرعة الصحيحة لطفلك وكيف ومتى سيتم إعطاء الحقنة.</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية أو مخاوف متعلقة باستخدام هذا الدواء لطفلك، فاسأل الطبيب أو الممرضة اللذين يقومان بإعطاء الحقنة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، يمكن أن تسبب ركازة دوبوتامين أعراضًا جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL">سيفحص طبيبك قلبك قبل إعطائك ركازة دوبوتامين ليقرر إذا ما كان مناسبًا لك تلقي العقار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن الأعراض الجانبية التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>شائعة جدًا (أكثر من مريض واحد من بين كل 10 مرضى)</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة معدل نبضات القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات ضربات القلب</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>شائعة (تصيب أقل من مريض واحد من بين كل 10 مرضى، ولكن أكثر من مريض واحد من بين كل 100 مريض)</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع أو انخفاض ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق الأوعية الدموية (تضيق الأوعية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام نبضات القلب (الخفقان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض تشبه الربو (التشنج القصبي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في عدد خلايا الدم البيضاء (كثرة اليوزنيات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تثبيط تكون الجلطات الدموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي (طفح ظاهر)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الوريد في موضع الحقن (الالتهاب الوريدي)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>غير شائعة (تصيب أقل من مريض واحد من بين كل 100 مريض، ولكن أكثر من مريض واحد من بين كل 1000 مريض)</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة انقباضات بطينات القلب (تسرع القلب البطيني)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقباضات غير متحكم بها في بطينات القلب (الرجفان البطيني)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية (احتشاء عضلة القلب)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>نادرة جدًا (تصيب أقل من مريض واحد من بين كل 10000 مريض، بما في ذلك الحالات المعزولة)</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء نبضات القلب (بطء القلب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم إمداد القلب بقدر كافٍ من الدم (إقفار عضلة القلب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض البوتاسيوم (نقص بوتاسيوم الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع على الجلد (نزيف حبري)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحصار القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق الأوعية الدموية التي تقوم بإمداد القلب (تشنج وعائي تاجي)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>غير معروفة (لا يمكن التنبؤ بها من خلال البيانات المتاحة)</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر بسبب الإجهاد (اعتلال عضلة القلب الناتج عن الإجهاد)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية (تفاعلات فرط الحساسية) بما في ذلك أعراض الطفح الجلدي، والحمى، وزيادة عدد خلايا الدم البيضاء (كثرة اليوزنيات)، وأعراض تشبه الربو (التشنج القصبي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية شديدة (تفاعلات تأقية) ونوبات ربو شديدة تهدد الحياة يحتمل أن تكون بسبب الحساسية تجاه ميتابيسلفيت الصوديوم (انظر القسم 2)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنج العضلي (الرمع العضلي) في المرضى الذين يعانون من فشل كلوي شديد ويتلقون دوبوتامين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتيجة غير طبيبعية لاختبار وظائف القلب (ارتفاع مقطع ST في مخطط كهربية القلب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب عضلة القلب (التهاب عضلة القلب اليوزيني) في المرضى الذين أجروا عملية زراعة قلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحصار القلب (انسداد مسلك التدفق الخارجي للبطين الأيسر)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمزق عضلة القلب المميت</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التململ</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالرغبة في التقيؤ (الغثيان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشكشكة والوخز (مذل)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرعاش</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الرغبة في التبول (مع الجرعات المرتفعة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالحرارة والقلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنج العضلي (التقلص الرمعي العضلي)</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي بشأنها. يتضمن هذا أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الأعراض الجانبية مباشرةً عبر نظام الإبلاغ القومي. بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">للإبلاغ عن الأعراض الجانبية</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية</p><ul><li dir="RTL">فاكس: +966-11-205-7662</li><li dir="RTL">للاتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات. هاتف: +966-11-2038222، تحويلة: 2317-2356-2340</li><li dir="RTL">الهاتف المجاني: 19999</li><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني: <u>&nbsp;</u>https//ade.sfda.gov.sa/</li></ul><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL"><strong>دول الخليج الأخرى:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تقع مسؤولية إعطائك الجرعة الصحيحة واستخدام هذا الدواء والتخلص منه على طبيبك والصيدلي</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد مرور تاريخ انتهاء الصلاحية المدون على العبوة الكرتون/الملصق.</p><p dir="RTL">يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء إذا لاحظت أن المحلول غير صافٍ وخالٍ من الجسيمات أو إذا كانت الحاوية تالفة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم الصيدلي الذي تتعامل معه بالتخلص من أي دواء يظل غير مستخدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قم بتخزينه في درجة حرارة أقل من 25 درجة مئوية. احفظه بعيدًا عن الضوء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المكون الفعال هو هيدروكلوريد دوبوتامين. كل 1 مل يحتوي على هيدروكلوريد دوبوتامين بما يكافئ 12.5 ملجم من دوبوتامين في محلول معقم للحقن.</p><p dir="RTL">المكونات الأخرى هي ميتابيسلفيت الصوديوم، وماء للحقن.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>تم تزويد ركازة دوبوتامين في قارورة زجاجية صافية سعة 20 مل، في عبوات كرتونية تحتوي على قارورة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق والمصنع</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;Pfizer&nbsp;Australia Pty Ltd, Australia</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong><strong>&nbsp;</strong><strong>الجهة المصنعة:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;Hospira Australia Pty Ltd, Australia</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أغسطس/آب 2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dobutamine 12.5 mg/ml concentrate for solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml contains Dobutamine Hydrochloride equivalent to Dobutamine 12.5 mg.
Each vial contains 250 mg Dobutamine in 20ml.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adult population</p><p>&nbsp;</p><p>Dobutamine 12.5 mg/ml concentrate for solution for infusion is indicated in adults who require inotropic support in the treatment of low output cardiac failure associated with myocardial infarction, open heart surgery, cardiomyopathies, septic shock and cardiogenic shock. Dobutamine 12.5 mg/ml concentrate for solution for infusion can also increase or maintain cardiac output during positive end expiratory pressure (PEEP) ventilation.</p><p>&nbsp;</p><p>Dobutamine stress echocardiography (Adult population only)</p><p>&nbsp;</p><p>Dobutamine 12.5 mg/ml concentrate for solution for infusion may also be used for cardiac stress testing as an alternative to exercise in patients for whom routine exercise cannot be satisfactorily performed. This use of dobutamine should only be undertaken in units which already perform exercise stress testing and all normal care and precautions required for such testing are also required when using dobutamine for this purpose.</p><p>&nbsp;</p><p>Paediatric population</p><p>&nbsp;</p><p>Dobutamine is indicated in all paediatric age groups (from neonates to 18 years of age) as inotropic support in low cardiac output hypoperfusion states resulting from decompensated heart failure, following cardiac surgery, cardiomyopathies and in cardiogenic or septic shock.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Route of Administration: For intravenous use only.</p><p><strong><em>Adult population</em></strong><strong> </strong></p><p>Dobutamine 12.5 mg/ml concentrate for solution for infusion must be diluted to at least 50 ml prior to administration in an IV container with one of the intravenous solutions listed below:</p><p>Sodium Chloride Intravenous Infusion BP</p><p>5% Dextrose Intravenous Infusion BP</p><p>5% Dextrose + 0.9% Sodium Chloride Intravenous Infusion BP</p><p>5% Dextrose + 0.45% Sodium Chloride Intravenous Infusion BP</p><p>Sodium Lactate Intravenous Infusion BP</p><p>For example, diluting to 250 ml or 500 ml will provide the following concentrations for administration:</p><p>250 ml contains 1,000 micrograms/ml of dobutamine</p><p>500 ml contains 500 micrograms/ml of dobutamine</p><p><strong>The prepared solution should be used within 24 hours.</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Because of its short half-life, Dobutamine 12.5 mg/ml concentrate for solution for infusion is administered as a continuous intravenous infusion. After dilution, it should be administered through an intravenous needle or catheter using an IV drip chamber or other suitable metering device to control the rate of flow.</p><p>Recommended dosage for adults and the elderly: The usual dose is 2.5 to 10 micrograms/kg/minute. Occasionally, a dose as low as 0.5 micrograms/kg/minute will produce a response.</p><p>Rarely, up to 40 micrograms/kg/minute may be required.</p><p>The rate of administration and the duration of therapy should be adjusted according to the patient&#39;s response as determined by heart rate, blood pressure, urine flow, and if possible, measurement of cardiac output.</p><p>It is advisable to reduce the dosage of dobutamine hydrochloride gradually rather than abruptly stopping therapy.</p><p>Side-effects, which are dose-related, are infrequent when Dobutamine 12.5 mg/ml concentrate for solution for infusion is administered at rates below 10 micrograms/kg/minute. Rates as high as 40 micrograms/kg/minute have been used occasionally without significant adverse effects.</p><p>The final volume administered should be determined by the fluid requirements of the patient. Concentrations as high as 5,000 micrograms/ml have been used in patients on a restricted fluid intake. High concentrations of Dobutamine 12.5 mg/ml concentrate for solution for infusion should only be given with an infusion pump, to ensure accurate dosage.</p><p><strong><em>Cardiac stress testing </em></strong><em>(Adult population only)</em></p><p>When used as an alternative to exercise for cardiac stress testing the recommended dose is an incremental increase of 5 micrograms/kg/minute, from 5 up to 20 micrograms/kg/minute, each dose being infused for 8 minutes. Continuous ECG monitoring is essential and the infusion terminated in the event of &gt; 3 mm ST segment depression or any ventricular arrhythmia. The infusion should also be terminated if heart rate reaches the age/sex maximum, systolic blood pressure rises above 220 mm Hg or any side effects occur.</p><p><strong><em>Pediatric population </em></strong></p><p>For all pediatric age groups (neonates to 18 years) an initial dose of 5 micrograms/kg/minute, adjusted according to clinical response to 2 &ndash; 20 micrograms/kg/minute is recommended. Occasionally, a dose as low as 0.5-1.0 micrograms/kg/minute will produce a response.</p><p>There is reason to believe that the minimum effective dosage for children is higher than for adults. Caution should be taken in applying high doses, because there is also reason to believe that the maximum tolerated dosage for children is lower than the one for adults. Most adverse reactions (tachycardia in particular) are observed when dosage was higher than/equal to 7.5 micrograms/kg/minute but reducing or termination of the rate of dobutamine infusion is all that is required for rapid reversal of undesirable effects.</p><p>A great variability has been noted between pediatric patients in regard to both the plasma concentration necessary to initiate a hemodynamic response (threshold) and the rate of hemodynamic response to increasing plasma concentrations, which demonstrates that the required dose for children cannot be determined a priori and should be titrated in order to allow for the supposedly smaller &ldquo;therapeutic width&rdquo; in children.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>For continuous intravenous infusion using an infusion pump, dilute to a concentration of 0.5 to 1 mg/mL (max 5mg/mL if fluid restricted) with Glucose 5% or Sodium Chloride 0.9%. Infuse higher concentration solutions through central venous catheter only. Dobutamine intravenous infusion is incompatible with bicarbonate and other strong alkaline solutions.</p><p><u>Neonatal intensive care:</u> Dilute 30 mg/kg body weight to a final volume of 50 mL of infusion fluid. An intravenous infusion rate of 0.5 mL/hour provides a dose of 5 micrograms/kg/minute.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to dobutamine, sodium metabisulfite or any of the other ingredients.
• Phaeochromocytoma. 
• Dobutamine stress echocardiography 
Dobutamine must not be used for detection of myocardial ischaemia and of viable myocardium in case of:
- recent myocardial infarction (within the last 30 days)
- unstable angina pectoris
- stenosis of the main left coronary artery
- haemodynamically significant outflow obstruction of the left ventricle including hypertrophic obstructive cardiomyopathy
- haemodynamically significant cardiac valvular defect
- severe heart failure (NYHA III or IV)
- predisposition for or documented medical history of clinically significant or chronic arrhythmia, particularly recurrent persistent ventricular tachycardia
- significant disturbance in conduction
- acute pericarditis, myocarditis or endocarditis
- aortic dissection
- aortic aneurysm
- poor sonographic imaging conditions
- inadequately treated / controlled arterial hypertension
- obstruction of ventricular filling (constrictive pericarditis, pericardial tamponade)
- hypovolaemia
- previous experience of hypersensitivity to dobutamine

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Adult population</em></strong><strong> </strong></p><p>If an undue increase in heart rate or systolic blood pressure occurs, or if an arrhythmia is precipitated, the dose of dobutamine should be reduced or the drug should be discontinued temporarily.</p><p>Dobutamine may precipitate or exacerbate ventricular ectopic activity; rarely has it caused ventricular tachycardia or fibrillation. Because dobutamine facilitates A-V conduction, patients with atrial flutter or fibrillation may develop rapid ventricular responses.</p><p>Particular care is required when administering dobutamine to patients with acute myocardial infarction, as any significant increase in heart rate or excessive increases in arterial pressure that occur may intensify ischaemia and cause anginal pain and ST segment elevation.</p><p>Inotropic agents, including dobutamine, do not improve haemodynamics in most patients with mechanical obstruction that hinders either ventricular filling or outflow, or both. Inotropic response may be inadequate in patients with markedly reduced ventricular compliance. Such conditions are present in cardiac tamponade, valvular aortic stenosis, and idiopathic hypertrophic subaortic stenosis.</p><p>Minimal vasoconstriction has occasionally been observed, most notably in patients recently treated with a &beta;-blocking drug. The inotropic effect of dobutamine stems from stimulation of cardiac &beta;<sub>1</sub> receptors and this effect is prevented by &beta;-blocking drugs. However, dobutamine has been shown to counteract the cardiodepressive effects of &beta;-blocking drugs. Conversely, adrenergic blockade may make the &beta;<sub>1</sub> and &beta;<sub>2</sub> effects apparent, resulting in tachycardia and vasodilatation.</p><p><strong><em>Dobutamine stress echocardiography</em></strong><strong> </strong></p><p>Because of possible life-threatening complications, the administration of dobutamine for stress echocardiography should only be undertaken by a physician with sufficient personal experience of the use of dobutamine for this indication.</p><p>The use of Dobutamine 12.5 mg/ml concentrate for solution for infusion as an alternative to exercise for cardiac stress testing is not recommended for patients with unstable angina, bundle branch block, valvular heart disease, aortic outflow obstruction or any cardiac condition that could make them unsuitable for exercise stress testing (see section 4.3)</p><p>Cardiac rupture is a potential complication of myocardial infarction. The risk of cardiac rupture (septal and free wall) may be influenced by a variety of factors including site of, and time since, infarct. There have been very rare, fatal reports of acute cardiac rupture during dobutamine stress testing. These events have occurred during pre-discharge examination in patients hospitalised with recent (within 4-12 days) myocardial infarction. In the reported cases of free wall rupture, resting echocardiogram showed a dyskinetic and thinned inferior wall. Patients considered at risk of cardiac rupture during dobutamine testing should therefore be carefully evaluated prior to testing.</p><p>Dobutamine stress echocardiography must be discontinued if one of the following diagnostic endpoints occurs:</p><p>- reaching the age-predicted maximal heart rate [(220-age in years) x 0.85]</p><p>- systolic blood pressure decrease greater than 20 mmHg</p><p>- blood pressure increase above 220/120 mmHg</p><p>- progressive symptoms (angina pectoris, dyspnoea, dizziness, ataxia)</p><p>- progressive arrhythmia (e.g. coupling, ventricular salvos)</p><p>- progressive conduction disturbances</p><p>- recently developed wall motility disorders in more than 1 wall segment (16-segment model)</p><p>- increase of endsystolic volume</p><p>- development of repolarisation abnormality (due to ischaemia horizontal or down sloping ST segment depression more than 0.2 mV at an interval of 80 (60) ms after the J point compared to baseline, progressive or monophasic ST segment elevation above 0.1 mV in patients without a previous myocardial infarction</p><p>- reaching peak dose</p><p>In the event of serious complications (see section 4.8) dobutamine stress echocardiography must be stopped immediately.</p><p>During the administration of Dobutamine 12.5 mg/ml concentrate for solution for infusion, as with any parenteral catecholamine, heart rate and rhythm, arterial blood pressure and infusion rate should be monitored closely. When initiating therapy, electrocardiographic monitoring is advisable until a stable response is achieved.</p><p>Precipitous decreases in blood pressure have occasionally been described in association with dobutamine therapy. Decreasing the dose or discontinuing the infusion typically results in rapid return of blood pressure to base-line values, but rarely intervention may be required and reversibility may not be immediate.</p><p>Dobutamine 12.5 mg/ml concentrate for solution for infusion should be used with caution in the presence of severe hypotension complicating cardiogenic shock (mean arterial pressure less than 70 mm Hg).</p><p>Hypovolaemia should be corrected when necessary with whole blood or plasma before administering dobutamine.</p><p>If arterial blood pressure remains low or decreases progressively during administration of dobutamine despite adequate ventricular filling pressure and cardiac output, consideration may be given to the concomitant use of a peripheral vasoconstrictor agent, such as dopamine or noradrenaline.</p><p>Dobutamine 12.5 mg/ml concentrate for solution for infusion contains sodium metabisulfite. Sulfites may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Sulfite sensitivity is seen more frequently in asthmatic than non-asthmatic people.</p><p><strong><em>Pediatric population</em></strong><strong> </strong></p><p>Dobutamine has been administered to children with low-output hypoperfusion states resulting from decompensated heart failure, cardiac surgery, and cardiogenic and septic shock. Some of the haemodynamic effects of dobutamine hydrochloride may be quantitatively or qualitatively different in children as compared to adults. Increments in heart rate and blood pressure appear to be more frequent and intense in children. Pulmonary wedge pressure may not decrease in children, as it does in adults, or it may actually increase, especially in infants less than one year old. The neonate cardiovascular system has been reported to be less sensitive to dobutamine and hypotensive effect seems to be more often observed in adult patients than in small children.</p><p>Accordingly, the use of dobutamine in children should be monitored closely, bearing in mind these pharmacodynamic characteristics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Halogenated anaesthetics:</em></p><p>Although it is less likely than adrenaline to cause ventricular arrhythmias, Dobutamine 12.5 mg/ml concentrate for solution for infusion should be used with great caution during anaesthesia with cycloproprane, halothane and other halogenated anaesthetics.</p><p><em>Entacapone</em>:</p><p>The effects of Dobutamine 12.5 mg/ml concentrate for solution for infusion may be enhanced by entacapone.</p><p><em>Beta-blockers</em>:</p><p>The inotropic effect of dobutamine stems from stimulation of cardiac beta<sub>1</sub> receptors, this effect is reversed by concomitant administration of beta-blockers. Dobutamine has been shown to counteract the effect of beta-blocking drugs. In therapeutic doses, dobutamine has mild alpha<sub>1</sub>- and beta<sub>2</sub>-agonist properties. Concurrent administration of a non-selective beta-blocker such as propranolol can result in elevated blood pressure, due to alpha-mediated vasoconstriction, and reflex bradycardia. Beta-blockers that also have alpha-blocking effects, such as carvedilol, may cause hypotension during concomitant use of dobutamine due to vasodilation caused by beta<sub>2</sub> predominance (see section 4.4 Special warnings and precautions for use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Use in pregnancy</em></p><p>Dobutamine did not cause teratogenic effects or affect fertility in trials on rats and rabbits.&nbsp; There have been no studies in humans on use during pregnancy.</p><p>Dobutamine should not be used during pregnancy unless the potential benefits to the woman outweigh the potential risks to the fetus.</p><p><em>Use in lactation</em></p><p>There have been no studies in humans on use during lactation.&nbsp; Should it be necessary to administer dobutamine to nursing mothers, breastfeeding should be suspended during the period of exposure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable in view of the indications for use and the short half-life of the drug.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Adult population</em></strong><strong> </strong></p><p>Infusions for up to 72 hours have revealed no adverse effects other than those seen with shorter infusions. There is evidence that partial tolerance develops with continuous infusions of Dobutamine 12.5 mg/ml concentrate for solution for infusion for 72 hours or more; therefore, higher doses may be required to maintain the same effects.</p><p>Evaluation of undesirable effects is based on the following frequency scale:</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>&ge; 1/10</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>&ge; 1/100 to &lt; 1/10</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>&ge; 1/1,000 to &lt; 1/100</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>&ge; 1/10,000 to &lt; 1/1,000</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>&lt; 1/10,000</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>cannot be estimated from the available data</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Immune system disorders:</u></p></td></tr><tr><td style="vertical-align:top"><p>Not Known:</p></td><td colspan="2" style="vertical-align:top"><p>Hypersensitivity reactions including rash, fever, eosinophilia and bronchospasm have been reported. Anaphylactic reactions and severe life-threatening asthmatic episodes may be due to sulfite sensitivity (see section 4.4 Special warnings and other precautions for use).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Blood and lymphatic system disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Eosinophilia, inhibition of thrombocyte aggregation (only when continuing infusion over a number of days)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Metabolism and nutrition disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td colspan="2" style="vertical-align:top"><p>Hypokalaemia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Nervous system disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td colspan="2" style="vertical-align:top"><p>Paraesthesia, tremor, myoclonic spasm. Myoclonus has been reported in patients with severe renal failure receiving dobutamine</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Cardiac disorders / vascular disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td colspan="2" style="vertical-align:top"><p>Increase of the heart rate by &ge; 30 beats/min</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Blood pressure increase of &ge; 50 mmHg. Patients suffering from arterial hypertension are more likely to have a higher blood pressure increase.</p><p>Blood pressure decrease, ventricular dysrhythmia, dose-dependent ventricular extrasystoles.</p><p>Increased ventricular frequency in patients with atrial fibrillation. These patients should be digitalised prior to dobutamine infusion.</p><p>Vasoconstriction in particular in patients who have previously been treated with beta receptor blockers.</p><p>Anginal pain, palpitations</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Ventricular tachycardia, ventricular fibrillation</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td colspan="2" style="vertical-align:top"><p>Bradycardia, myocardial ischaemia, myocardial infarction, cardiac arrest</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td colspan="2" style="vertical-align:top"><p>Electrocardiogram ST segment elevation</p><p>Decrease in pulmonary capillary pressure</p><p>Eosinophilic myocarditis has been noted in explanted hearts of patients who had undergone treatment with multiple medications including dobutamine or other inotropic agents prior to transplantation.</p><p><u>Children:</u> pronounced increase of heart rate and/or blood pressure as well as a lower decrease of the pulmonary capillary pressure than adults. Increase of pulmonary capillary pressure in children under 1.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Gastrointestinal disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td colspan="2" style="vertical-align:top"><p>Nausea</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Psychiatric disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td colspan="2" style="vertical-align:top"><p>Restlessness, feeling of heat and anxiety</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Renal and urinary disorder</u></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td colspan="2" style="vertical-align:top"><p>Urinary urgency</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Dobutamine stress echocardiography</em></strong></p><p><u>Cardiac disorders / vascular disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td colspan="2" style="vertical-align:top"><p>Pectoral anginal discomfort, ventricular extra-systoles with a frequency of &gt; 6/min</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Supraventricular extrasystoles, ventricular tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td colspan="2" style="vertical-align:top"><p>Ventricular fibrillation, myocardial infarction</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td colspan="2" style="vertical-align:top"><p>Occurrence of a second degree atrioventricular block, coronary vasospasms.</p><p>Hypertensive/hypotensive blood pressure decompensation, occurrence of an intracavitary pressure gradient, palpitations</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td colspan="2" style="vertical-align:top"><p>Stress cardiomyopathy</p><p>Left ventricular outflow tract obstruction</p><p>Fatal cardiac rupture</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Respiratory system, thoracic and mediastinal disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Bronchospasm, shortness of breath</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Gastrointestinal disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Nausea</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Skin and subcutaneous tissue disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Exanthema</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td colspan="2" style="vertical-align:top"><p>Petechial bleeding</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Musculoskeletal and connective tissue disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Chest pain</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>Renal and urinary disorders</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Increased urgency at high dosages of infusion</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><u>General disorders and administration site conditions</u></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td colspan="2" style="vertical-align:top"><p>Fever, phlebitis at the injection site</p><p>In case of accidental paravenous infiltration, local inflammation may develop.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td colspan="2" style="vertical-align:top"><p>Cutaneous necrosis</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong><em>Paediatric population</em></strong><strong> </strong></p><p>The undesirable effects include elevation of systolic blood pressure, systemic hypertension or hypotension, tachycardia, headache, and elevation of pulmonary wedge pressure leading to pulmonary congestion and edema, and symptomatic complaints.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after <u>marketing</u> authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions <u>according to their local requirements. </u></p><p>To reports any side effect(s):</p><p><strong>Saudi Arabia: </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):</p><ul><li>Fax: +966-11-205-7662</li><li>Call NPC at +966-11-2038222, Ext 2317-2356-2340</li><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p><strong>Other GCC States:</strong></p><p> Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdoses of Dobutamine 12.5 mg/ml concentrate for solution for infusion have been reported rarely. The symptoms of toxicity may include anorexia, nausea, vomiting, tremor, anxiety, palpitations, headache, shortness of breath and anginal and non-specific chest pain. The positive inotropic and chronotropic effects of dobutamine may cause hypertension, tachyarrhythmias, myocardial ischaemia and ventricular fibrillation. Hypotension may result from vasodilatation.</p><p>The duration of action of Dobutamine 12.5 mg/ml concentrate for solution for infusion is generally short (half-life, approximately 2 minutes). Dobutamine 12.5 mg/ml concentrate for solution for infusion should be temporarily discontinued until the patient&#39;s condition stabilises. The patient should be monitored and any appropriate resuscitative measures initiated promptly.</p><p>Forced diuresis, peritoneal dialysis, haemodialysis, or charcoal haemoperfusion have not been established as beneficial.</p><p>If the product is ingested, unpredictable absorption may occur from the mouth and gastrointestinal tract.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code C01CA07</p><p><strong>&nbsp;</strong></p><p><strong><em>Adult population </em></strong></p><p>Dobutamine directly stimulates &beta;-adrenergic receptors and is generally considered a selective &beta;<sub>1</sub>-adrenergic agonist, but the mechanisms of action of the drug are complex. It is believed that the &beta;-adrenergic effects result from stimulation of adenyl cyclase activity. In therapeutic doses, dobutamine also has mild &beta;<sub>2</sub> - and &alpha;<sub>1</sub> - adrenergic receptor agonist effects, which are relatively balanced and result in minimal net direct effect on systemic vasculature. Unlike dopamine, dobutamine does not cause release of endogenous norepinephrine. The main effect of therapeutic doses of dobutamine is cardiac stimulation. While the positive inotropic effect of the drug on the myocardium appears to be mediated principally via &beta;<sub>1</sub>-adrenergic stimulation, experimental evidence suggests that &alpha;<sub>1</sub>-adrenergic stimulation may also be involved and that the &alpha;<sub>1</sub>-adrenergic activity results mainly from the (-) -stereoisomer of the drug.</p><p>The &beta;<sub>1</sub>-adrenergic effects of dobutamine exert a positive inotropic effect on the myocardium and result in an increase in cardiac output due to increased myocardial contractility and stroke volume in healthy individuals and in patients with congestive heart failure. Increased left ventricular filling pressure decreases in patients with congestive heart failure. In therapeutic doses, dobutamine causes a decrease in peripheral resistance; however, systolic blood pressure and pulse pressure may remain unchanged or be increased because of augmented cardiac output. With usual doses, heart rate is usually not substantially changed. Coronary blood flow and myocardial oxygen consumption are usually increased because of increased myocardial contractility.</p><p>Electrophysiologic studies have shown that dobutamine facilitates atrio-ventricular conduction and shortens or causes no important change in intraventricular conduction. The tendency of dobutamine to induce cardiac arrhythmias may be slightly less than that of dopamine and is considerably less than that of isoproterenol or other catecholamines. Pulmonary vascular resistance may decrease if it is elevated initially and mean pulmonary artery pressure may decrease or remain unchanged. Unlike dopamine, dobutamine does not seem to affect dopaminergic receptors and causes no renal or mesenteric vasodilatation; however, urine flow may increase because of increased cardiac output.</p><p><strong><em>Paediatric population</em></strong><strong> </strong></p><p>Dobutamine also exhibits inotropic effects in children, but the haemodynamic response is somewhat different than that in adults. Although cardiac output increases in children, there is a tendency for systemic vascular resistance and ventricular filling pressure to decrease less and for the heart rate and arterial blood pressure to increase more in children than in adults. Pulmonary wedge pressure may increase during infusion of dobutamine in children 12 months of age or younger.</p><p>Increases in cardiac output seems to begin at iv infusion rates as low as 1.0 micrograms/kg/minute, increases in systolic blood pressure at 2.5 micrograms/kg/minute, and heart rate changes at 5.5 micrograms/kg/minute.</p><p>The increase of dobutamine infusion rates from 10 to 20 micrograms/kg/minute usually results in further increases in cardiac output.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Adult population </em></strong></p><p>Absorption: Orally administered dobutamine is rapidly metabolised in the GI tract. Following IV administration, the onset of action of dobutamine occurs within 2 minutes. Peak plasma concentrations of the drug and peak effects occur within 10 minutes after initiation of an IV infusion. The effects of the drug cease shortly after discontinuing an infusion.</p><p>Distribution: It is not known if dobutamine crosses the placenta or is distributed into milk.</p><p>Elimination: The plasma half-life of dobutamine is about 2 minutes. Dobutamine is metabolised in the liver and other tissues by catechol-o-methyltransferase to an inactive compound, 3-0-methydobutamine and by conjugation with glucuronic acid. Conjugates of dobutamine and 3-0-methyldobutamine are excreted mainly in urine and to a minor extent in faeces.</p><p><strong><em>Paediatric population</em></strong><strong> </strong></p><p>In most paediatric patients, there is a log-linear relationship between plasma dobutamine concentration and hemodynamic response that is consistent with a threshold model.</p><p>Dobutamine clearance is consistent with first-order kinetics over the dosage range of 0.5 to 20 micrograms/kg/minute. Plasma dobutamine concentration can vary as much as two-fold between paediatric patients at the same infusion rate and there is a wide variability in both the plasma dobutamine concentration necessary to initiate a hemodynamic response and the rate of hemodynamic response to increasing plasma concentrations. Therefore, in clinical situations dobutamine infusion rates must be individually titrated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No further information other than that which is included in the Summary of Products Characteristics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium metabisulfite.</p><p>Water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dobutamine Hydrochloride Injection when diluted to 250 micrograms/mL and 500 micrograms/mL with 0.9% Sodium Chloride Injection and 5% Glucose Injection, was found to be stable for 24 hours at room temperature and in the presence of fluorescent light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
Do not use Dobutamine Hydrochloride after the expiry date which is stated on the Vial label after EXP:. The expiry date refers to the last day of that month.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C. Protect from light.</p><p>Keep out of the sight and reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dobutamine Hydrochloride Injection is a sterile solution containing in each 20 mL vial, Dobutamine Hydrochloride 280.2 mg (250 mg Dobutamine equivalent) and Sodium Metabisulfite.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Contains no antimicrobial preservative</p><p>Following dilution use in one patient on one occasion and discard any residue.</p><p>Do not dilute with alkaline solutions</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER	
Pfizer Australia Pty Ltd, Australia
MANUFACUTRED BY
Hospira Australia Pty Ltd, Australia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2018 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>